HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Dec.15)-BMS/Biokin $8.4B Eye-Popping Deal, NRDL Negotiation Result, Haoyuan

China's Central Economic Work Conference – Something You May Not Be Aware Of

Pfizer Inc (PFE US) - Continue to Lose Its Way in the Post-Pandemic Era

Genscript Biotech (1548.HK) - Inadequate Cognition Will Lead to Bad Investment Decisions

Pre-IPO Fangzhou Group - The Business and the Concerns

2023 High Conviction Update: Sonoscape Medical (300633.CH) - High Growth Is Expected to Continue

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Thematic (Sector/Industry)

Hong kong Pharmaceuticals, biotechnology and life sciences / Thematic (Sector/Industry)

<ul>
<li>China has pointed out to strengthen and expand cooperation with the industrial chain/supply chain of neighboring countries. Countries along the Belt and Road would be key partners in the future. </li>
<li>In addition to traditional low value-added consumables, a group of high-tech/high value-added equipment that conform to the technical trend are gradually becoming important export products, which implies great investment opportunities.</li>
<li>We listed related companies that would benefit from the vigorous development of the Belt and Road project. Their global revenue proportion would further increase, which worth investors’ attention.</li>
</ul>


China has pointed out to strengthen and expand cooperation with the industrial chain/supply chain of neighboring countries. Countries along the Belt and Road would be key partners in the future. 
In addition to traditional low value-added consumables, a group of high-tech/high value-added equipment that conform to the technical trend are gradually becoming important export products, which implies great investment opportunities.
We listed related companies that would benefit from the vigorous development of the Belt and Road project. Their global revenue proportion would further increase, which worth investors’ attention.


The Belt and Road Initiative – Investment Opportunities in China Healthcare